multiple sclerosis

News

Novartis sets sights on new oral MS drug after phase 3 wins

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.

News

As patents expire, fampridine is cleared for NHS use in MS

Several years after other UK nations, people living with multiple sclerosis in England are finally able to get NHS treatment with fampridine.

R&D

The changing multiple sclerosis landscape: Earlier diagnosis...

Multiple sclerosis (MS) is undergoing a meaningful evolution in how it is understood, diagnosed, and managed.

News

New data build case for Roche's oral BTK drug for MS

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

MSD and Mayo Clinic team up on AI drug discovery

MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.

Novartis sets sights on new oral MS drug after phase 3 wins

As patents expire, fampridine is cleared for NHS use in MS

The changing multiple sclerosis landscape: Earlier diagnosis...

New data build case for Roche's oral BTK drug for MS

After phase 3 clean sweep, Roche plans oral BTK filing in MS

MSD and Mayo Clinic team up on AI drug discovery

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

multiple sclerosis

Editor's Picks